TopoⅡα在乳腺癌中的表达与蒽环类药物敏感性的分析(3)
 |
| 第1页 |
参见附件。
[11] Nielsen KV，Ejlertsen B，Mφller S，et al.The value of TOP2A gene copy number variation as a biomarker in breast cancer：Update of DBCG trial 89D[J].Acta On-col，2008，47(4)：725-734.
[12] Tubbs R，Barlow WE，Budd GT，et al.Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status[J].J Clin Oncol，2009，27(24)：3881-3886.
[13] K noop AS，K nudsen H，B alslev E，et al.retrospective analysis of topoisom erase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide，methotrexate，and fluorouracil or cyclophosphamide，epirubicin，and fluorouracil：Danish Breast Cancer Cooperative G roup[J].J Clin Oncol，2005，23(30)：7483-7490.
[14] Tanner M，Isola J，Wiklund T，et a l.Topoisomerase alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer：Scand inavian B reast G roup Tria l9401[J].J Clin Oncol，2006，24(16)：2428-2436.
(收稿日期：2013-07-04)
您现在查看是摘要介绍页，详见PDF附件。